Company

Nirogy Therapeutics, Inc.

Nirogy Therapeutics develops small molecules targeting cellular transport proteins.

About

Nirogy Therapeutics researches solute carrier and monocarboxylate transporters, including inhibitors being developed for triple negative breast cancer. Founded in 2013, it is based in Massachusetts, US, and received a USD 2 million NIH/NCI SBIR grant in September 2020.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in